Adrenocorticotrophin (ACTH) is formed from the cleavage of pro-opiomelanocortin. Measurement of plasma ACTH is a key step in the differential diagnosis of hypothalamic-pituitary-adrenal disorders.
bLPH to b-endorphin (31aa) and g-lipotrophin (gLPH, 56 aa) and N-POC to g 3 -MSH (26 aa). gLPH and bendorphin contain the sequences for bMSH (22 aa) and met-encephalin (5 aa), respectively, but whether these peptides are produced is controversial. Both PC1 and PC2 cleave their substrate peptides on the Cterminal side of polybasic residues, but they have slightly di¡erent speci¢cities, and their di¡erent distribution in the pituitary accounts for the di¡erences in processing of POMC in the anterior and intermediate pituitary lobes. 2 Cleavage of POMC in the hypothalamus 3 and the skin 4 by both PC1 and PC2 results in production of the smaller peptides, which have a paracrine action in these target tissues. Diagrammatic representation of proopiomelanocortin processing by prohormone convertase 1 (PC1) and prohormone convertase 2 (PC2). The amino acid sequence number relative to human pro-opiomelanocortin is given for the N-and C-terminal amino acids for each of the processed peptides. POMC, pro-opiomelanocortin; pro-ACTH, proadrenocorticotrophin; bLPH, b-lipotrophin; N-POC, N-terminal pro-opiomelanocortin; JP, joining peptide; ACTH, adrenocorticotrophin; g 3 -MSH, g 3 -melanocyte-stimulating hormone; aMSH, a-melanocyte-stimulating hormone; CLIP, corticotrophin-like intermediate lobe peptide; gLPH, g-lipotrophin; bEP, b-endorphin; PC, prohormone convertase. The ¢rst 24 amino acids of ACTH are highly conserved, whilst there are minor species di¡erences in the C-terminal portion of the molecule.
Bioactivity and half-life
The biological activity of ACTH resides in amino acids 1-18, although amino acids 19-39 in£uence activity primarily by a¡ecting ACTH half-life. The disappearance of ACTH from the circulation is rapid, with a circulating half-life dependent on assay methodology. By bioassay, this is 8-14 min, 5 but immunoassays suggest both shorter 6 or longer 7 clearance times.
Regulation and action
The synthesis of ACTH in the corticotrophs is regulated primarily by the hypothalamic peptide corticotrophic releasing factor (CRF) and arginine vasopressin, although a range of other factors can in£uence ACTH production. ACTH increases adrenal gland steroidogenesis and cortisol secretion and synthesis of new adrenal proteins. ACTH is under long-loop' negative feedback control whereby increasing concentrations of cortisol inhibit ACTH secretion.
It has been reported that POMC has little biological activity, 8, 9 whilst pro-ACTH is equipotent with ACTH in the dispersed rat adrenal cell bioassay (AC Hale et al., personal communication) but 8-33% as potent in a cytochemical ACTH bioassay. 10 However, it is not known whether POMC and pro-ACTH bind to the ACTH receptor (MC2-R) and other MSH receptors (MC1-R, MC3-R, MC4-R and MC5-R). 11 Biological activity of ACTH precursors in human subjects has been deduced from clinical studies. 12 In 24 patients with pigmentation related to postadrenalectomy Cushing's disease, concentrations of both ACTH and ACTH precursors correlated with pigmentation score. 13 Patients with ectopic ACTH syndrome due to small cell lung carcinoma have been shown to secrete primarily ACTH precursors which must either have biological activity when present at very high concentrations or be cleaved to ACTH in the periphery. 14 However, relative ACTH precursor biological potency must be low, as normal cortisol concentrations were seen in subjects with invasive pituitary macro-adenomas with circulating ACTH precursor concentrations of 2000 pmol/ L. 12 
Clinical reasons for requests for ACTH measurement
In our experience, ACTH measurements are often inappropriately requested. A common example of an inappropriate ACTH request is to include it in the initial work-up of a patient with suspected Cushing's syndrome. It is important to measure ACTH in the di¡erential diagnosis of pituitary Cushing's syndrome, particularly in the diagnosis of the ectopic ACTH syndrome and in subjects undergoing bilateral inferior petrosal sinus catheter sampling with CRF stimulation. ACTH measurement is also of value in the di¡erential diagnosis of adrenocortical insu¤ciency (Addison's disease), the monitoring of ACTHproducing pituitary tumours (e.g. Nelson's syndrome) and the diagnosis of hypopituitarism with ACTH de¢ciency.
Measurement of ACTH in Cushing's syndrome To distinguish between ACTH-dependent and ACTH-independent Cushing's syndrome
If the presence of excess glucocorticoids in patients with proven Cushing's syndrome has been established, then low concentrations of circulating ACTH would indicate that there is an adrenal tumour secreting glucocorticoids which are feeding-back on the pituitary to inhibit secretion of ACTH. Normal or raised ACTH concentrations are suggestive of a pituitary or ectopic source of ACTH.
ACTH measurements can be useful in the follow-up of patients after surgical treatment for pituitarydependent Cushing's syndrome. The presence of continuing inappropriately raised ACTH concentrations may indicate inadequate tumour removal after pituitary surgery, and increasing concentrations after adrenalectomy may indicate the development of Nelson's syndrome. Details of treatment (e.g. metyrapone and time of last dose) are relevant to the interpretation of the ACTH concentration and need to be available to the laboratory.
Differential diagnosis of pituitary-dependent Cushing's disease and ectopic ACTH syndrome
The ectopic ACTH syndrome accounts for 15% of cases of Cushing's syndrome and by de¢nition refers to the production of ACTH by non-pituitary tumours. Most commonly these tumours are small cell lung carcinoma, carcinoma of the thymus or pancreas, phaeochromocytoma, medullary carcinoma of the thyroid and bronchial adenomas/carcinoids. 8,15^19 Clinically, the condition can be di¤cult to distinguish from pituitary-dependent Cushing's syndrome, with circulating ACTH concentrations overlapping in both conditions. 14, 20 However, there is evidence from chromatographic separation methods that higher molecular weight ACTH precursors are present in the circulation of patients with the ectopic ACTH syndrome. 10, 21, 22 This led to the suggestion that elevated ACTH precursors could provide a diagnostic advantage compared to ACTH. Subsequently, a direct immunoassay for the determination of ACTH precursors was developed. 23 Stewart et al. 14 found that 15 patients with ectopic ACTH syndrome had a median (range) ACTH precursor concentration of 2194 (139-18 000) pmol/ L compared with a median of 33 pmol/L for patients with pituitary-dependent Cushing's syndrome (P50.001), whilst there was considerable overlap in ACTH concentrations. The median (range) ACTH precursor/ACTH molar ratio in subjects with ectopic ACTH syndrome was 48 (7-316) (P50.01) compared with 4 (2-12) for patients with Cushing's disease and 3 (1-10) for controls. More recently, we investigated whether ACTH precursors could be diagnostically valuable in patients with ectopic ACTH syndrome caused by carcinoid tumours. 12 Twelve patients with carcinoid tumours had median (range) ACTH precursor concentrations of 544 (151-1300) pmol/L and ACTH concentrations of 79.5 (31.8-200 ) ng/L [17.5 (7-44) pmol/ L]. In contrast, median (range) ACTH precursor concentrations for other ectopic tumours were 1911 (139-18 000) pmol/L and ACTH concentrations of 227.3 (4.5-2564) ng/L [50 (1-564) pmol/ L]. However, importantly, ACTH precursor measurement di¡erentiated between carcinoid tumours and pituitary micro-adenomas (see Fig. 3 ).
ACTH precursor measurements provide valuable diagnostic discriminatory evidence of the ectopic ACTH syndrome for any endocrinologist who requests them. In addition, measurement by our laboratory of ACTH precursors has been used by endocrine centres throughout the UK, Europe, Japan and the USA as a diagnostic tool in di¤cult cases of Cushing's syndrome. The potential demand for ACTH precursor requests is di¤cult to assess as we are currently the only centre o¡ering this service. A non-isotopic kit version of the ACTH precursor assay is now commercially available (IDS Ltd, Boldon, Tyne and Wear, UK).
Measurement of ACTH in subjects undergoing inferior pituitary venous sinus sampling
Bilateral inferior petrosal sinus sampling is a useful investigative technique in the di¡erential diagnosis of ACTH-dependent Cushing's syndrome. Accurate diagnosis of pituitary-derived ACTH hypersecretion is of paramount importance in order to direct the removal of corticotroph tumours by trans-sphenoidal surgery. On occasion, basal gradients in ACTH concentrations between central and peripheral samples are su¤cient to establish pituitary hypersecretion. 24 However, the diagnostic sensitivity of this procedure is greatly improved by the assessment of the central to peripheral ACTH gradients obtained following the administration of corticotrophinreleasing hormone (CRH) to stimulate ACTH secretion. 25 Bilateral inferior petrosal sinus sampling is an expensive, technically demanding procedure with a success rate dependent on experience, and may be uncomfortable for the patient. Besides failure to place both catheters properly, the complications range from inguinal haematomas to permanent damage of the brain stem. 26 The incidence of complications ranges from 0.2% to 23%, 15 and it is recommended that it is carried out in a centre experienced in the technique. Catheters are inserted into both femoral veins and guided towards the sinuses with the aid of imaging and contrast material. Blood is withdrawn simultaneously from both petrosal sinuses and a peripheral vein (715 min). A second set of basal samples is usually obtained (710 min) to gain information on the degree of stress, as this increases the ACTH concentration. A bolus injection of CRH (ovine or human, 100 mg) at 0 min is given into an arm vein and samples are obtained simultaneously from both inferior petrosal sinuses (IPS) and a peripheral vein at speci¢ed time points (3, 5, 10 and 20 min) up to 30 min after the administration of CRH. 24 Generally, the highest response is observed in the early samples after CRH administration. Patients undergoing this procedure should be rendered hypercortisolaemic as suppression of the normal corticotrophs is required for detection of ACTH gradients. 27 IPS and peripheral ACTH concentrations can be very high following CRH administration. Results should therefore be analysed with caution if the immunoassay employed is subject to antigen excess hook e¡ects'. 28 High IPS compared to peripheral ACTH concentrations is indicative of a pituitary origin of ACTH. In a recent critical analysis of IPS sampling, 67 of 69 patients with Cushing's disease had a median (standard error of the mean, SEM) IPS to peripheral ratio of plasma ACTH of 9.5 (1.4) rising to a maximum of 55.8 (7.5) following CRH treatment, whilst two patients had a ratio less than 2 (i.e. diagnostic sensitivity of 97% and speci¢city of 100% in diagnosing Cushing's disease). 25 In contrast, six patients with ectopic ACTH had a maximal IPS to peripheral ratio of 1.3 (0.16) which did not change following CRH stimulation. In a larger study of 203 patients with Cushing's disease and 17 patients with ectopic ACTH syndrome, 15 an IPS to peripheral ratio of plasma ACTH of 5 2 in either of the two basal sets of samples, or 5 3 after CRH injection, gave diagnostic accuracy, sensitivity and speci¢city of the procedure as 100%. However, this is not a useful procedure for determining on which side the corticotrophin-secreting adenoma is located. An inter-sinus ratio of 5 1.4 has been suggested as being consistent with the ipsilateral localization of a micro-adenoma, 27 and a review of reports documenting its use 18 revealed a diagnostic accuracy of 78% (range 50 -100%) compared with ¢ndings of pituitary surgery.
Measurement of ACTH in Nelson's syndrome
The combination of enlargement of a pituitary ACTHsecreting tumour following bilateral adrenalectomy in addition to increased secretion of ACTH and related peptides (aMSH) leading to skin pigmentation is termed Nelson's syndrome. Cushing's syndrome is only rarely caused by a pituitary macro-adenoma and more often it is due to small pituitary adenomas. Although trans-sphenoidal pituitary microsurgery has become the treatment of choice in Cushing's disease, other procedures, such as bilateral adrenalectomy and pituitary irradiation, are currently in use in its management. 29 The proportion of Cushing's patients treated by bilateral adrenalectomy varies among institutions. A study of 162 patients with pituitary-dependent Cushing's disease at one institution 30 reported that pituitary surgery was successful in 79 of 103 patients, whilst of 63 patients undergoing bilateral adrenalectomy 87.1%, 79.3% and 71.2% remained free of Nelson's syndrome after 2, 7 and 10 years, respectively. Of the 30% of patients who go on to develop a demonstrable pituitary tumour, this may be large enough to produce local pressure symptoms in about 10% of subjects. 31 In addition, this expanding tumour secretes ACTH-related peptides, which can result in increased pigmentation of the skin and mucosa.
In Nelson's syndrome, there is no correlation between the concentration of plasma ACTH and tumour size, so this test is not useful to assess tumour burden as a monitor. The presence of ACTH in the cerebrospinal £uid is an indication that a tumour has extended beyond the diaphragma sellae.
Ray et al. 13 investigated ACTH precursor concentrations following adrenalectomy for Cushing's disease. Of the 24 subjects studied, ¢ve had no evidence of pigmentation or pituitary tumour progression. ACTH precursors were higher in post-adrenalectomy Cushing's disease (median 97.5 pmol/L, range 26 -647 pmol/L, P50.001) than in untreated Cushing's disease (median 29 pmol/ L, range 9-104 pmol/L) and normal controls (5-40 pmol/L). Processing of ACTH precursors to ACTH was found to be enhanced postadrenalectomy with a median (SEM) ACTH precursor/ ACTH ratio of 1.0 (0.5) compared with 5.6 (0.8) for Cushing's disease and 5.3 (0.9) for normal subjects.
Differentiation of primary and secondary adrenal insuf ciency: Addisonian crisis
ACTH measurement has little role to play in the diagnosis of Addison's disease. However, in a patient with proven adrenal insu¤ciency, a raised ACTH concentration indicates a primary (adrenal) cause, whereas a normal or low concentration would indicate that the de¢ciency is due to a pituitary abnormality. It is important that samples are taken before the initiation of steroid therapy as this can make the interpretation of the ACTH result di¤cult.When the measurement of ACTH is requested, results of cortisol measured during a Synacthen test should be sent as this provides supporting evidence.
Follow-up of patients on steroid replacement
ACTH measurement in patients on steroid replacement for Addison's disease or congenital adrenal hyperplasia can sometimes be of value if there are doubts about adequacy of adrenal steroid replacement. Avery high ACTH concentration would indicate lack of compliance or inadequate steroid replacement.
Results of ACTH measurements should always be interpreted with respect to the time of administration of the replacement glucocorticoid. Details of treatment, including type of glucocorticoid, dose and time of last dose, should be given with all requests.
Measurement of ACTH in subjects with large invasive pituitary tumours
It is recognized by endocrinologists that some patients found to have large invasive pituitary tumours with no clinical evidence of Cushing's disease may, on removal of the tumour, have immunohistochemical evidence of positive staining for ACTH-related peptides. In a study of six patients with macro-adenomas, 32 two had no evidence of Cushing's syndrome. Retrospective analysis showed that these patients had elevated concentrations of ACTH precursors in the circulation with relatively little circulating ACTH. 32 This type of tumour is di¤cult to remove completely and therefore the patient should be monitored for recurrence of tumour by determining when there is signi¢cant increase in ACTH precursors in the circulation.
Congenital ACTH de ciency
ACTH de¢ciency is a rare disorder which may present in the neonatal period, usually with hypoglycaemia. In a 6-week-old child experiencing hypoglycaemic ¢ts, Nussey et al. 33 reported that, whilst ACTH concentrations were not detectable, ACTH precursor concentrations were clearly measurable prior to treatment and were stimulated by CRH. Dexamethasone treatment suppressed ACTH precursor concentrations. DNA sequencing of the coding region of the POMC gene revealed no abnormalities, which suggests that isolated congenital ACTH de¢ciency may be a consequence of abnormal PC1 cleavage enzyme defects.
POMC mutations have been reported in two patients with undetectable basal and CRH-stimulated ACTH concentrations, obesity and red hair pigmentation. 34 In patient 1, a paternal allele transversion (G7013T) and maternal allele deletion (C7133) were identi¢ed in exon 3 with predicted POMC protein truncations at codon 79 and codon 131, respectively. Due to the structural changes introduced by these two mutations, POMC-derived ACTH, aMSH and b-endorphin would be lost. In patient 2, a homozygous transversion (C3804A) in exon 2, 11 base pairs upstream from the start codon, would abolish translation of the wild-type protein.
Standardization of ACTH assays
There is no generally accepted human international reference preparation for ACTH. The di¡erent centres o¡ering clinical ACTH measurement rely on a limited selection of human puri¢ed and synthetic preparations. Dobson et al. 35 examined the relative potency of four synthetic ACTH 1-39 preparations from the National Hormone and Pituitary Program (NHPP, Harbor-UCLA Medical Centre, Los Angeles, CA, USA), Bachem UK Ltd and Universal Biologicals and a puri-¢ed human ACTH standard (National Institute for Biological Standards and Control, NIBSC code 74/555) in a two-site immunoradiome tric assay (IRMA). Analysis of variance revealed signi¢cant di¡erences (P50.001) between the Universal Biologicals and Bachem preparations compared with the NIBSC and NHPP standards. The Universal Biologicals preparation was the most potent, closely followed by the Bachem standard. The NIBSC and NHPP preparations had the lowest potencies. These di¡erences are such that, for a sample giving 1000 counts in the IRMA, the ACTH concentration could be 50, 58, 92 or 106 ng/L (11, 12.8, 20.2 and 23.3 pmol/ L) 35 when read from the UBL, Bachem, NIBSC and NHPP standard curves, respectively.
Unlike the two commercial preparations, both NIBSC and NHPP materials have been assigned a biological potency (in terms of international units, IU) as calibrated against the third international standard for ACTH (of porcine origin, known to contain impurities). The World Health Organization establishes international standards (IS) and reference preparations (IRP) for substances of biological or synthetic origin that cannot be adequately characterized by chemical means alone. IRPs were often assigned IU potency, especially when early de¢nition of such a unit was desirable to prevent the emergence of several di¡erent ways of describing potency. An IS is a preparation to which an IU of activity has been assigned, generally on the basis of an international collaborative study. The standard is intended for use in the estimation of potency of an appropriate test sample by direct comparison in suitable biological test systems.
Although the IU values assigned to the NIBSC (12.4 IU per 50 mg) and NHPP (4.7 IU per 50 mg) preparations di¡er signi¢cantly, being approximately three-fold higher for the NIBSC standard, the immunoreactive potencies of the two standards in the ACTH IRMA are similar. Di¡erences in the potency of commercial preparations may be a consequence of any combination of factors, including weighing errors, presence of salts or solvents and presence of`error peptides' produced during synthesis.
Until an ISP for human ACTH is available it is essential that each centre measuring ACTH de¢nes the standard used in its assay system and derives a normal reference range for the assay based on this preparation.
Methodology of ACTH assays Bioassays
Bioassays rely upon a functional e¡ect and give information about the biological potency of the molecule, whereas immunoassays rely upon the detection of an antigenic site and give information about the concentration of that antigen.
In vivo bioassays use whole animals, whereas in vitro assays utilize isolated organs, tissue slices or cell preparations. The ¢rst bioassay for ACTH utilized large numbers of hypophysectomized rats and involved the measurement of adrenal gland ascorbic acid concentrations where one gland was removed prior to injection of ACTH and the other one removed 1h after injection of ACTH. 36 The sensitivity of this assay was 0.2 mIU, equivalent to 2610 79 g (third IS). Alternatively, corticosterone output in venous blood 37 in response to intravenous injections (0.05-0.2 mL) of test samples and ACTH samples o¡ered improved sensitivity (0.005 mIU, 5610 711 g), but assay precision was poor due to variation in response among animals and required considerable technical expertise.
The bene¢ts of in vitro over in vivo assays include improved sensitivity, precision, reduced cost of animals, speed and assay through-put. The cytochemical bioassay relates biochemical activity to histology in guinea pig adrenal gland sections. 38 Following treatment with standard or plasma, the sections are reacted with Prussian blue stain to assess reducing capacity (ascorbate depletion) and colour intensity determined by integrating microdensitometry. This assay is highly sensitive to 5610 712 g ACTH (third IS) with good precision and can measure plasma samples diluted 5 1:100. The cytochemical bioassay for ACTH has three main limitations: (a) the assay through-put of 27-36 samples per week is low; (b) the assay requires a high degree of operator skill; and (c) the relationship between reducing capacity (ascorbate depletion) of the zona reticularis and corticosteroidogenesis has not been de¢ned. 39 Lowry et al. 40 described an in vitro bioassay [50% e¡ective dose (ED 50 ) 50 ng/L, 11pmol/ L, for human pituitaryACTH] utiliz ing rat adrenal cells dispersed by trypsin digestion and mechanical agitation. However, heparinized plasma spiked with ACTH altered the shape of the dose -response curve so that ACTH could not be assayed quantitatively in plasma. Subsequently, Mitchell et al. 41 described an in vitro bioassay (sensitivity 12 ng/L, 2.64 pmol/L; NIBSC 74/555) of immunoextracted plasma for ACTH based on cortisol secreted by cultured guinea pig adrenal cells. Immunoextraction of ACTH with a solid-phase ACTH monoclonal antibody to ACTH residues 25-39 isolates ACTH and ACTH precursor molecules. Immunoextraction also circumvents plasma interference with the assay.
Immunoassays (Table 1) Radioimmunoassay (RIA)
The measurement of ACTH by RIA has proved di¤cult due to:
. The rarity and expense of high-avidity antisera. 42, 43 . Di¤culties associated with reliably producing a high-quality radioligand. Iodination of ACTH can cause instability, and it is recommended that shorter iodination times are used in order to label only one of the two tyrosine residues. Both chloramine T and lactoperoxidase can be used for iodination if these considerations are taken into account. . The low concentrations of circulating ACTH in normal subjects. The sensitivity of RIAs is not adequate for determination of subnormal concentrations of circulating ACTH. Extraction procedures involving binding of ACTH to crushed porous glass to increase the concentration of ACTH prior to measurement 44 and increasing assay incubation times (in excess of 42 h) 45, 46 have been employed to improve assay sensitivity. However, these adaptations have made the measurement of ACTH technically demanding.
Immunometric assays
The use of ACTH RIAs have enabled considerable advances to be made in understanding the physiology of ACTH secretion in certain diseases. However, these assays have serious limitations in terms of sensitivity and speci¢city. Speci¢city is antibody-dependent, with di¡ering results obtained from N-and C-terminal ACTH-directed antisera. 47, 48 Good assay speci¢city is also vital due to the presence of circulating ACTH precursor molecules and fragments devoid of ACTH bioactivity.
The two-site immunometric assay relies on two antibodies binding two di¡erent epitopes of the ACTH peptide. In general, antibodies have been raised to Nand C-terminal regions of ACTH in order to ensure that ACTH 1-39 is detected rather than fragments derived from ACTH, such as aMSH and CLIP. Many of the assays still rely on 125 I-labelled antibodies and detection using a gamma counter. However, assays have been developed which use enzyme or europium labels. 49 IRMAs have overcome the necessity for iodinating ACTH and, because they employ excess antibody (excess reagent or non-competitive assay), they overcome the problem of requiring a high-a¤nity antibody as is needed for RIA. The Nichols CHEMI assay utilizes avidin-coated 6mm diameter polystyrene beads (streptavidin-coated magnetic particles for the Nichols Advantage) linked to an ACTH C-terminal-speci¢c biotinylated polyclonal antibody. The N-terminal ACTH 1-17-speci¢c monoclonal antibody is labelled with an acridinium ester. The high-a¤nity interaction between biotin and avidin allows for a speci¢c and e¤cient means of binding the sandwich. After incubation, the tubes containing the washed beads are placed into the luminometer. Immediately after addition of chemiluminescence reagents, light output is quantitated; this is proportional to ACTH concentration. Similar to the Nichols assay, the DPC Immulite system employs a bead-bound capture antibody. The detection antibody is conjugated to alkaline phosphatase. The Immulite's enzyme-ampli¢ed chemiluminescence results in thousands of photons being emitted rather than one or two photons per binding event. The sustained signal produced by the enzyme-enhanced chemistry allows multiple readings to be taken for more precise measurements.
Characteristics of available ACTH immunoassays Working range
It would be desirable to measure circulating ACTH concentrations in normal subjects (510-50 ng/ L, 52.2-11pmol/L) and high concentrations seen in subjects with tumours or following intra-pituitary sinus sampling and CRH treatment.
Sensitivities and detection limits
One de¢nition of limit of detection (analytical sensitivity) is generally taken as a multiple of between two and three times the standard deviation (SD) above the mean of the zero counts read from a typical standard curve. The best sensitivities reported are for commercial chemiluminescence and IRMAs (range 0.55-9 ng/L, 0.12-19.8 pmol/L) and in-house IRMAs (3.5 ng/L, 0.77 pmol/L, based on 2.5SD), with the RIA being the poorest (11ng/L, 2.42 pmol/L; ED 10 15 ng/ L, 3.3 pmol/ L). The matrix of the zero calibrator may not match non-speci¢c factors found in plasma; therefore, a detection limit calculated using multiples of SD from the zero standard using assay bu¡er alone should be treated with caution.
A more useful approach is to use the limit of quan-ti¢cation (functional sensitivity) de¢ned as the lowest concentration for which an inter-batch coe¤cient of variation (CV) of less than 20% can be achieved. This information or a comprehensive dose-related interassay CVover the full working range is not provided in the commercial assay kit inserts. For the in-house IRMA the inter-assay CV of the standard curve was 510% over the range 27 to 45000 ng/L (5.94 to 41100 pmol/ L), increasing to 20% at 10 ng/L (2.2 pmol/L). 50 Accuracy Accuracy of assays is generally determined by assessment of recovery of an ACTH preparation such as the NIBSC ACTH standard 74/555 or synthetic ACTH when added over a range of concentrations to a human plasma sample. Mean recoveries reported were between 97% and 112% (see Table 2 ). No information on recoveries was available for the in-house RIA 43 or the BRAHMS Dynotest assay. Other manufacturers have provided correlation data as an indication of accuracy compared to another commercially available assay (Nichols Chemiluminescence and Allegro assays and Mitsubishi). This information is no substitute for direct information on recovery of ACTH added to patients'samples.
There is evidence that ACTH manufactured by Bachem is recognized di¡erently in immunoassays, as compared to ACTH manufactured by Peninsula Laboratories, with mean (SD) recoveries of 118 (13)% and 96 (3)%, respectively. 51 Although absolute recovery depends entirely on the manufacturers' estimates of the mass of ACTH supplied, the betweenmethod di¡erences in relative recovery are likely to be real and of some signi¢cance. Severe under-recovery of NHPP human ACTH [35.4 (2.1)%; personal communication A Ellis, UK NEQAS] has been reported, whilst the between-method di¡erences were relatively modest, suggesting possible di¡erences in potency between synthetic and puri¢ed pituitary material.
One potential method of improving assay accuracy is to increase the concentration of solid-phase antibody in order to increase the sensitivity of the assay and therefore improve accuracy at the lower concentrations of the standard curve.
Imprecision
Imprecision may a¡ect the di¡erential diagnosis of whether a patient has the ectopic ACTH syndrome or pituitary-dependent Cushing's disease if there is a well-de¢ned cut-o¡ in the clinical range. Any imprecision in the measurement of ACTH may give a false positive or false negative result. However, in most instances, the diagnosis is made on a range of dynamic tests as well as measurement of ACTH and cortisol.
With the development of two-site immunometric assays, the precision of measurement of ACTH has vastly improved. Typical ¢gures for inter-batch imprecision based on manufacturer's kit information lea£ets, published information 47,50 and personal communication (LA Perry, St Bartholomew's Hospital, London, 2001) are shown in Fig. 4 . Care should be taken when interpreting these data as some manufacturers have not provided imprecision concentrations over the full working range of the assay.
Within-batch precision data appear to be generally satisfactory for all assays within the stated range. Between-batch imprecision concentrations of less than 20% are considered to be acceptable. 52, 53 Precision deteriorates at low ACTH concentrations. Imprecision of 24% at 40 ng/L (8.8 pmol/ L) for the in-house RIA 43 is not acceptable. Precision data on ACTH concentrations 510 ng/L (52.2 pmol/L) is only available for three immunoassays (BRAHMS Dynotest and Nichols Advantage and Chemiluminesence).
Linearity
To demonstrate linearity (i.e. parallelism), patients' samples of known concentration are diluted with sample diluent (e.g. zero standard) or assay bu¡er. Observed values are compared with expected values. Regression analysis indicates whether there are matrix e¡ects upon dilution of the sample. For all assays described, with the exception of the CIS IRMA (see Table 2 ), information on linearity was provided. With the exception of the in-house RIA, all assays indicate that patients' samples gave responses parallel to the dose -response curve on dilution. The explanation given for non-parallelism of patients' samples in the in-house RIA was due to interference with antigen-antibody binding by high molecular weight proteins that could not be extracted by repeated silicic acid treatment. 43 This problem could be minimized by including appropriate concentrations of hormone -free plasma, so that the binding in all assay tubes would be similarly reduced (not practical for a high-volume assay laboratory) or by inclusion of silicic acid treated bovine serum albumin (3.5%, w/v). However, certain samples (controls and patients) still exhibited nonparallelism on dilution in an RIA such as this.
Method speci city/cross-reactivity
For ACTH-related peptides, the in-house RIA appears to be the least speci¢c of all assays (see Table 2 ). This is because the assay is dependent on the detection of a single epitope present on the ACTH N-terminal region (within ACTH [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Speci¢city in relation to ACTH fragments is improved considerably with two-site immunoassays that incorporate antibodies recognizing both the C-and N-terminal regions. For twosite assays, analytes can be recognized (i.e. increase signal) or interfere negatively with antibody binding (i.e. decrease signal; see Table 2 ). Loss of speci¢city may arise from haemolysed blood samples, which can interfere in the assay. Comprehensive data on negative interference is not provided in the kit inserts produced by manufacturers. Erroneous results of suppressed endogenous ACTH concentrations following synthetic ACTH 1-24 infusion have been reported when measured by the Nichols IRMA. 54 On investigation, this has been shown to be due to binding of synthetic ACTH 1-24 to the N-terminal capture antibody but not the C-terminal antibody without forming a detectable sandwich complex. Therefore, ACTH 1-24 negatively interferes with ACTH 1-39 binding when antibody concentrations become limited. 55, 56 Information on assay recognition of ACTH precursor molecules (pro-ACTH and POMC) is only provided for the in-house IRMA with a cross-reactivity of 50.1% for POMC and between 0.4% and 10% for pro-ACTH. Between-batch imprecision proles for commercially available and in-house adrenocorticotrophin (ACTH) immunoassays based on data provided by kit inserts, published information 43, 47, 50, 69, 70 and personal communication. ., DPC; m , Nichols Chemiluminescence; . , Nichols Advantage; r , Nichols Allegro; ., Salford immunoradiometric assay (IRMA); & , BRAHMS Dynotest; n , CIS; , , Mitsubishi IRMA; e , Euro-Diagnostica; s , in-house radioimmunoassay (RIA); x, extracted RIA. CV, coef cient of variation.
From our own studies, high concentrations of ACTH precursors ( 5 4200 pmol/ L) appear to interfere negatively with the Nichols assay. 28 Consequently, erroneously lowÀCTH' concentrations will be reported in conditions where ACTH precursors are high, such as in the ectopic ACTH syndrome, Nelson's syndrome and patients with large invasive pituitary macro-adenomas. However, the occurrence of this is rare.
In samples where ACTH precursors are present in excess of ACTH, such as in the ectopic ACTH syndrome, the ACTH precursors will cross-react to varying degrees in di¡erent ACTH assays. 14 It is important to know the degree of cross-reactivity of precursors, although none of the commercially available assays have this information. There is also the problem that high concentrations of ACTH precursors can cause a`hook e¡ect' in some assays, resulting in a falsely lowACTH concentration. 28 
High-dose 'hook effect'
Two-site immunoassays are susceptible to a`hook e¡ect' where, above a certain sample concentration, the response is no longer proportional to concentration and indeed the response falls. At very high analyte concentrations, capture and labelled antibodies become limiting, leading to competition between analyte and analyte-labelled antibody for free solid-phase capture antibodies. The problem can be overcome by the sequential addition of reagents (including a wash step; i.e. heterogeneous as opposed to homogeneous assay), using excess capture and labelled antibody or by assaying samples at two dilutions. All these solutions have time and cost implications.
The DPC, Nichols, in-house IRMA 50 and Euro-Diagnostica assays are suitable for measuring ACTH concentrations of less than 908 000, 20 000, 5000 and 50 000 ng/L (199 760, 4400, 1100 and 11000 pmol/ L), respectively. The CIS Bio International and Nichols IRMA kit inserts recommend dilution or multiple dilutions of samples if high values are anticipated.
Acceptable degree of inaccuracy
Accuracy has been assessed by either correlation with a previously de¢ned method and/or recovery of ACTH spiked into samples. Mean recoveries (see Table 2 ) of between 97% and 112% (DPC Immulite and Salford IRMA) have been reported; however, the UK NEQAS reports much greater variation in accuracy. 51, 57 
Speed convenience and cost
The majority of laboratories measuring ACTH use automated high-capacity immunoassay analysers with which results can be obtained in a little over 1h (e.g. DPC Immulite). ACTH requests are rarely urgent, which enables samples to be batched for convenience. The total assay time for the in-house ACTH IRMA 50 is 8 h; however, shorter assay times can be achieved using non-isotopic formats 49 due to automated washing procedures and shorter counting times. The cost of commercial automated assays is di¤cult to calculate as reagent costs depend on total workload, number of quality controls run, range of analytes measured and variable equipment purchase/hire and maintenance costs. In-house methods usually have lower consumable costs but increased sta¡ costs.
Specimen requirements Sample timing and handling
ACTH is secreted in a pulsatile manner superimposed on a diurnal circadian rhythm with a maximum between 06:00 and 08:00 h. 58 The mean pulse frequency for men and women is 18 and 10 per 24 h, respectively, with a mean peak amplitude of 16.8 and 10.3 ng/L (3.7 and 2.3 pmol/ L), respectively. 59 Due to the poor sensitivity of early assays, it was customary to take samples between 08:00 and10:00 h, when ACTH concentrations would be at their highest. However, the e¡ects of diurnal variation on ACTH plasma concentrations are less during the early afternoon.
It is advised to collect whole blood into lithium heparin or EDTA plastic tubes, taking note of the sample requirement of the immunoassay to be used (see Table 2 ). Use of inappropriate sample collection containers usually results in abnormally low ACTH concentrations.
Glass tubes must be siliconized as ACTH sticks to glass. Samples should be kept cool and centrifuged within 1h of collection, and the plasma transferred into plastic or siliconized glass tubes. Grossly haemolysed samples cannot be used. Multiple freeze-thaw cycles should be avoided; ideally, two separate aliquots (minimum 500 mL) of the sample should be stored at less than 7208C. Samples should be transported frozen on dry ice to the reference laboratory.
ACTH is not measured in urine. However, ACTH has been measured in cerebrospinal £uid, although there are high concentrations of ACTH precursors 60 and if these cross-react in ACTH assays there may be an inappropriately high result.
ACTH can be extracted from tissue samples such as pituitary and extra-pituitary tumours. Tissue should be chopped or ground frozen (with dry ice) 61 prior to homogenization in acid (1 M acetic or 0.1 M HCl) with protease inhibitors (phenylsulphonyl£uoride 0.3 mg/ mL and pepstatin 10 mg/mL). Following centrifugation, the supernatant is lyophilized. The dried sample is then reconstituted in 0.01 M HCl and diluted in appropriate assay bu¡er. 62 Alternatively, the lyophilized supernatant is resuspended in tri£uoroacetic acid (0.1%) and further puri¢ed on C18 Sep-Pak cartridges (Waters Associates, Millford, MA, USA). 61
Storage conditions
Historically it has been suggested that ACTH is unstable (ACTH half-life spiked into thawed plasma is 197-286 min and into whole blood is 44 -70 min). 5 Consequently, special precautions for the handling of blood specimens are widely advocated 63, 64 and samples are spun immediately and the plasma collected and stored at 7708C until assay. This is the method of choice because it is unclear whether certain samples may degrade more rapidly than others. However, there are some data which indicate that endogenous bioactive and immunoreactive ACTH is stable for at least 1h in heparinized blood and 2 h in plasma. 50, 65 Thus, ACTH is relatively stable and it may even be possible to undertake one or two freeze -thaw cycles before samples degrade. However, if a result is inappropriately low it is important to assess the storage history.
Quality assessment of ACTH measurement Internal quality control of ACTH assays
Due to the labile nature of ACTH in serum, the quality control (QC) of all available ACTH assays presents particular problems. Care should be taken in the preparation and storage of internal QC samples for ACTH assays. QC samples should either be stored freeze-dried or, if in liquid form, in small aliquots at 7708C. At the preparation stage, a su¤cient number of aliquots should be produced for the full lifetime of the QC material. Storage of QC samples in large volumes should be avoided, as changes in ACTH concentration may occur on thawing and refreezing of the samples.
Although there are a few commercial suppliers of ACTH QC material, most users of ACTH assays will either employ QC samples provided with the assay kit or will prepare in-house QC material. QC samples will usually be prepared by spiking plasma with known amounts of standard ACTH. It is important that the nature of the standard material is known, as assay performance may be in£uenced by the ACTH preparation being measured. In addition, it is important that the matrix of the QC sample matches as closely as possible that of the patients' samples as some assays may have di¡erent assay performance characteristics with di¡erent matrices, especially if preservatives or stabilizers have been added.
As for all internal QCs, the range of ACTH concentration in the samples should be relevant to that encountered in clinical samples. For ACTH it is especially important that QC samples at the low end of the quoted reference range are included, as assays often show poor precision at the lower end of their standard curve.
External quality assessment of ACTH assays
There are external quality assessment (QA) schemes for ACTH estimation (UK NEQAS, Edinburgh, UK; INSTAND Surveys, Du« sseldorf, Germany; CAP Surveys, North¢eld IL, USA), but at the present time there are no external schemes for ACTH precursor measurement. A major problem with the provision of an external QA scheme for ACTH is the instability of the hormone in plasma. In the UK NEQAS scheme, pools are prepared in EDTA plasma and freeze-dried prior to distribution. In order to obtain elevated ACTH concentrations, a high proportion of the pools issued contain added ACTH. Similar samples are used in the German INSTAND scheme.
Overall agreement between laboratories is poor (geometric coe¤cient of variation 25%), although in general the major methods do show acceptable between-laboratory agreement. However, there is still variability in between-laboratory measurement of ACTH in individual pools even at similar concentrations. Due to the lack of a recognized international standard, true recovery experiments are not possible, but the UK NEQAS scheme has performed recovery experiments employing a synthetic ACTH preparation (see section on accuracy).
In the German INSTAND scheme, more than 85% of participants now use non-isotopic methodologies. As in the UK scheme, overall agreement among laboratories is poor, even among laboratories using the same methodology, with samples containing added ACTH giving particular problems. The stability of the pools has been found to be good (less than 5% deterioration per year in the ACTH concentration of lyophilized samples). Variability among laboratories using the same methodology is therefore probably due to sample handling.
All schemes have a relatively small number of participants, which may present di¤culties in deriving a valid target against which to compare laboratory performance. Another important drawback in interpretation of the QA scheme results is the lack of an international standard with an assigned value in mass units, which are used by most methods.
There are currently 54 centres measuring ACTH who participate in the UK NEQAS scheme; 51 this suggests that this assay is more usually performed in specialist laboratories. Details of the principal immunoassays used for determination of ACTH are shown in Table 1 . In the UK scheme, there has been a steady increase in the number of laboratories using nonisotopic methods over the last few years. In 1999, the number of laboratories using non-isotopic methods exceeded isotopic users for the ¢rst time. In general, most laboratories (50 of 54) are now using commercially available kits based on two-site immunometric assays, with a minority using RIAs (one direct and one extracted) or in-house radiometric assays (two). Of the 52 laboratories employing two-site immunometric assays, 34 methods are chemiluminescence based and 18 radioisotope based. The most popular method in use has been the DPC Immulite, used by 32% of laboratories in 1999 57 and 44% (including the DPC Immulite 2000 method) in 2000. 51
Future developments
Assay automation o¡ers considerable bene¢ts to laboratories in terms of convenience, speed of sample through-put and processing of single samples (hence no need to batch samples). The use of stored master curves eliminates the need for frequent calibration. Diagnostic Products Corporation Ltd have now introduced their Immulite 2000 system in addition to the Immulite assay and allows samples to be analysed in batch, random access or urgent (stat) sample modes. Nichols Institute Diagnostic Ltd has recently launched its own automated chemiluminescence assay: the Nichols Advantage Speciality System. The detection antibody is labelled with acridinium ester and the solid-phase antibody is biotinylated, which will bind with high a¤nity to streptavidin-coated magnetic beads allowing e¤cient sample washing. Three di¡erent assay formats are o¡ered with varying incubation times (total test time of 40 min) and sample through-put (up to 170 results per h). In the simultaneous assay format, antibodies and solid phase are incubated with the sample at the same time. Sequential assay format antibodies are incubated with the samples prior to addition of streptavidin-coated magnetic particles. The two-step assay format involves binding of one antibody and solid phase to the antigen followed by a second incubation after washing and is particularly useful for samples containing high analyte concentrations which might result in a highdose hook e¡ect. Finally, two trigger solutions are injected into the reaction vessels; this initiates a chemiluminescence reaction and the light emission is quanti¢ed by a luminometer.
A new type of immunoassay for ACTH has recently been described and is now marketed by Beckman Coulter; this involves the succinylation of the e-amino group of lysine and the N-terminal amino group of ACTH. 66 The procedure improves the immunogenicity of ACTH. The coated-tube assay format consists of two capture antibodies speci¢c to the 18-24 and 25-39 amino acid regions of succinylated ACTH and an iodinated detection antibody speci¢c to the 1-13 region. The assay shows no appreciable cross-reaction with ACTH 1-10, ACTH 18-39 and ACTH 11-24 or aMSH. However, ACTH 1-24 cross-reacted slightly (9-10%). 66 Furthermore, POMC (at an unspeci¢ed concentration) and CLIP (45000 ng/ L) did not interfere. 67 Succinylation appears to stabilize ACTH in plasma with an average loss of 0.7% when stored for at least 4 h at 378C and 3.6% when stored for 1 week at 48C. An initial clinical comparison of the assay with the ELSA ACTH assay (CIS Bio International) showed close correlation. 67 In ACTH-hypersecreting syndromes of tumoural (Cushing's disease and ectopic ACTH secretion) or non-tumoural (Addison's disease and congenital adrenal hyperplasia) origin, a good agreement between the two assays was observed except for very high plasma ACTH values (41000 ng/L, 42200 pmol/L), and in some tumours where the succinylated ACTH IRMA yielded lower results in some cases. The authors believe that this discrepancy is due to the presence of circulating CLIP detected by the CIS Bio International assay.
The measurement of ACTH is important for improving our understanding of ACTH-related disorders and is likely to remain of value to specialist laboratories. Devolvement to non-specialist laboratories as this assay becomes available on more automated analysers is unlikely as the workload for the assay is relatively low. In addition, measurement of ACTH precursors has provided important information on abnormal ACTH processing, particularly in the ectopic ACTH syndrome. It is likely that in the future we will learn more about the regulation of ACTH processing and how this contributes to relative changes in prohormones and their derived peptides.
In the clinical and research setting, there has been increased interest in POMC and the derived ACTH and MSH peptides with the identi¢cation of two patients with a`POMC knockout mutation' which resulted not only in adrenal insu¤ciency but also in pale skin, red hair and obesity. 34 This highlights the importance of POMC processing in the hypothalamus where aMSH has a paracrine role in reducing food intake such that loss of gene expression results in obesity. There is also local expression of POMC in the skin where MSH peptides are important for skin pigmentation and hair colouring. The interaction between locally produced POMC peptides and those secreted by tumours is evidenced in the hyperpigmentation seen in ACTHrelated disorders. However, in the future, we have the opportunity to understand how di¡erent patterns of prohormone processing in di¡erent tissues results in these speci¢c e¡ects in diverse target tissues.
